Growth → value / healthcare rotation Rotation ▲ — five-name healthcare sleeve

McDonald (Jun 11): a Q4-2021-redux inflation shock in a multipolar world starts "the great migration" out of financial assets (bonds, the $41T NASDAQ-100, software) into value, hard assets and underowned sectors — growth-vs-value's break is "the beginning of a colossal move" (Berkshire-style owners of hard assets; S&P → Russell 2000). The crowded momentum factor (quants long semis / short healthcare, now 8% of the S&P vs 16%) turns at quarter-end: healthcare "a big winner the second half of the year" (ISRG/BAX as AI-data plays; Ceresna's XLV collar), with oil services (SLB "one of the most exciting trades in the market") the other AI beneficiary. Hay (Jun 12): back-to-back healthcare POW picks (DGX, then MDT) — the sector "as a whole looks undervalued and we're seeing a broad rotation into the space." Sohn (Jun 29, Strategas): healthcare has shrunk from 16% of the S&P to 8% ('its own GLP-1') after years of outflows — the most frustrating sector of the last three years, but performance so bad it is a reversion-to-mean candidate; meanwhile energy is 'coming off the boil' (a Feb-27 sugar-rush unwound by the ~Jun-15 oil collapse) and discretionary's chart 'looks like a recession' (the K-economy). Halftime committee (Jun 29): Lebenthal — healthcare, 'left for dead six months ago, is now the hot sector' (final trade Vertex), while energy is cold on the crude decline but worth waiting on for 'dividends, buybacks, attractive valuations.' Terranova — the healthcare leadership is on the 52-week-high list (Lilly, Merck). Bill Smead (Feb-05-26, back-fill): healthcare screens deeply undervalued vs the S&P — the expensed-R&D model (Merck/Amgen put 18–20% of revenue into medical-research institutes, expensed up front, then commercialize what works: "the most conservative income statement of anybody's"); bought UnitedHealth in Q4-25 at $300/$271 on the policy-headwind playbook that got them into BAC and JPM after the GFC, with Hemsley's insider buying the trigger — if the S&P loses money over the next decade and UNH compounds ~7% with dividends, that's the win. Finucane (Jul 16): pre-positions where the momentum money must rotate next — mandated/fully-invested sellers of semis have been recycling into financials, healthcare, utilities and staples, so Oxbow adds there while they're still sold off: recent long-term-growth adds IDEXX (niche-product pricing power), McKesson (GLP-1 distribution beneficiary) and US Bancorp ("the biggest, highest-quality super-regional"). 2026-AUG-07 — David Hay (Haymaker POW!): GILD an explicit Buy at ~$133 — the healthcare leg extended with a name mispriced by accounting rather than sector flows: a $10.5B Q2 GAAP loss that is "an accounting event, not a business event" masking ~$14B of adjusted operating income, a 7.6% forward FCF yield on a $163B cap, a ~70%-share HIV franchise (Biktarvy patents to 2036) funding Trodelvy's first-line oncology approvals, at 12–13× adjusted earnings vs the S&P's 20×; expects a re-rate to 15–16×. Bear case (IRA pricing + acquisition integration) requires both legs to be right simultaneously. 2026-AUG-07 — CNBC Halftime: healthcare the top three-month sector but flat over the last month, and the desk treats that as the setup. Simpson doubles Amgen post-earnings (beat-beat-raise; Maritide a potential once-monthly weight-loss shot), arguing "biotechs and healthcare can be some of the beneficiaries most quickly from AI." Harrington's sector thesis: "there's so much free cash being produced there and it's been undervalued and ignored and neglected" — Bristol-Myers at under 10× with $11B of FCF this year and $15B next, able to "buy their way to growth" through the patent cliff. 2026-JUN-16 (McDonald, historical): Healthcare halved from 16% to 8% of the S&P in five years "because all this money is moving into the technology" even as it creates the most US jobs; from a billionaire medtech family-office ideas dinner — ISRG and BAX as the AI-margin winners, AI making Intuitive's surgical-data moat "so much more valuable." 2026-08-17 — health care ranked first among defensives: "pharma and biotech and life sciences have been leadership. They remain the leadership. They act great." The notable part is the tail: "these reversals in some of these left for dead life science stocks are particularly notable. The thermos [Thermo Fisher] and the Danaher's and the Illumina's, which haven't been looked at in years — I think they put in major major bottoms." Managed care already bottomed and Verrone owns the miss: "these put major lows in late last year early this year. The UNH's of the world, the Signas [Cigna]. I got too dogmatic on those and I missed it. We try not to do that." Trennert's overhang: government's expanding role "worked for them for many years [and] it's obviously working against them now" wherever prices get set. (Verrone/Trennert on Eisman Ep 73, Aug 17) 2026-AUG-19 — Halftime (Terranova / Liz Thomas): The rotation got both a flow driver and a catalyst on the same day. Terranova's map: "capital is coming out of the momentum factor, out of memory, out of semiconductors. And it is excitingly going into healthcare and continuing to go into energy." The catalyst: Moderna more than doubled on the first-ever phase-3 of its Merck-partnered personalized cancer vaccine (met the melanoma endpoint alongside Keytruda). Liz Thomas supplies the durability test — last year's post-Mag-7 rotation into healthcare "didn't really stick… this time it's sticking, because now we have market movement upward both in technology and in healthcare" — plus the AI timing constraint: "healthcare is one of the next biggest beneficiaries of AI, but the cost of AI has to come down first… this is a sector you get paid to wait for. If you don't have a position right now, it is not too late." 2026-AUG-15 (Mark Newton, Fundstrat, Jimmy Connor): technical confirmation — healthcare "has broken out above almost a three-year downtrend relative to the S&P" after drug-pricing and ACA-subsidy pressure, and it is broad: "biotechnology, pharmaceutical stocks, HMOs." Slegers 2026-SEP-01: a fully disclosed quality book puts a number on the style drawdown — the portfolio beats the S&P 500 on every operating measure (ROE 33.3% vs 18.0%, ROIC 17.7% vs 14.5%, gross margin 63.8% vs 34.4%, FCF/net income 175% vs 70-90%, interest coverage 45.5 vs 14.6x, forward earnings growth 18.8% vs 13.0%) and on price (NTM P/E 18x vs 20x, 3-5yr EPS CAGR 14% vs 12%) — and loses badly on the only realised measure: a three-year CAGR of 1.3% against the index's 20.1% and 5.9% against 13.1% over five years. Portfolio FCF yield 6.0%, "their cheapest valuation level ever." Two live downgrades cut against the quality trade from inside: Novo Nordisk and Dino Polska cut on competition, not price (2026-AUG-23), with Novo showing flat 2025-28 EPS. Pieter Slegers (Compounding Quality), 2026-JAN-15 argues the GLP-1 duopoly has split on sentiment rather than economics: since 2020 Novo Nordisk's forward PE fell from 20.9x to 12.9x (−38%) while EPS rose from DKK 9 to DKK 23.5 (+161%), leaving it at 16.9x next year's earnings against Eli Lilly's 34.1x — "I don't think this huge valuation difference is justified." The reverse DCF (run on EPS rather than FCF because of heavy capacity capex) requires just 2.9% annual growth for a 10% return. The market share loss is conceded and reframed: GLP-1 share 59% → 50% and obesity share 74% → 53% in a year, against a market where "934 million people worldwide have obesity [and] only 2.2 million are currently treated with branded medication" and demand grows "more than 100% per year" — so revenue still sets records. A pure de-rating in the sector's largest franchise, with the counter-risk (Lilly's drug is simply more effective: 20% weight loss vs 14%) stated but not priced. 2026-SEP-04 (David Hay / Haymaker, Friday POW!): the rotation call is upgraded from preference to a constructed position, and stated as a forward sector view rather than a valuation observation: “healthcare and biotech are entering (or are in) a bullish recovery mode that will continue for the foreseeable future.” The INCY pick is explicitly framed as sector construction — “adding Incyte to the Haymaker portfolio is the continuation of the healthcare sleeve we started building with the inclusions of MDT and DGX in early June, as well as GILD a month ago” — making it a four-name overweight expressed through four uncorrelated drivers (medical devices, lab services, large-cap pharma cash flow, and a mid-cap biopharma with a clinical option). The house structure is the same in each: a base case that already clears the price, with the contested part taken as optionality — here ~16.5× 2026 EPS and ~4.3× EV/revenue on 40% net-sales growth, while “the consensus target of $127.13 is essentially at the current price… a Jakafi-plus-Opzelura base case with limited KRAS credit,” so “the market is paying almost nothing for a program that is showing 62% to 75% response rates in one of the most lethal cancers in existence.” The sector risk is named alongside: US drug pricing is not discussed, but the single-name risk carried into the sleeve is the 2028 patent cliff on ~55% of INCY’s net sales. 2026-SEP-04 — Fraser Jenkins dedicates a section of AllianceBernstein's paper to healthcare as the defensive sleeve inside a pro-equity view. It "sits at the nexus" of four forces: demographics (supportive, and specifically supportive of pricing power since "care costs tend to be quite sticky"), a plausible AI beneficiary, the need for diversification, and valuation — the sector's P/E relative to the market is low compared with its 20–30 year trading range even after outperforming. The decisive step is diagnosing why it is cheap: the discount is health-policy uncertainty, and "uncertainty about health policy is not particularly related to the riskiness of the AI trade in the near term, so it's a different kind of risk" — an uncorrelated risk factor is exactly what a concentrated AI-heavy portfolio needs. CNBC Halftime (2026-sep-11): healthcare has its worst week since March and Simpson buys UnitedHealth back after a year away — stopped out early 2025 near $355-360, bottomed near $235, re-entering because "the earnings are closer to a trough than a peak," with analysts guiding up and management near $20/share. Saccocia corroborates on the operating ratio ("UNH and others have gotten their medical loss ratios under control") and flags post-midterm optionality. Harrington is content to pause: healthcare "is only helped by AI... there's no version of AI that's going to make research harder." 2026-SEP-18 (Hay, Friday POW!): fifth healthcare-sleeve pick, AstraZeneca (AZN), a Buy at ~$164, 23% off its high after three trial setbacks in three months. It is bought on pipeline hit rate rather than a single catalyst (20+ Phase 3 readouts in 18 months; this week two wins, Enhertu DESTINY-Lung04 and Tagrisso, and one miss, camizestrant). Forward P/E ~14.9x vs market 21 and P/S 4.16x, both near decade lows last seen in 2016-17. Haymaker adds that AI is an underappreciated drug-discovery accelerant: pharma and biopharma 'will be some of the biggest winners from AI.'